SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in Peripheral Blood of Patients with Sickle Cell Disease
Robert M. Swift(John Brown University), Peter Gillette(SUNY Downstate Health Sciences University), Kisha Carrington(Kings County Hospital Center), Tracian James-Goulbourne(Kings County Hospital Center), Virdah Zaman(Long Island University), Kelsey Gustafson, Gurinder Sidhu(SUNY Downstate Health Sciences University), Qiukan Chen(Children's Hospital of Philadelphia), Osheiza Abdulmalik(Children's Hospital of Philadelphia), James E. Simon(Rutgers, The State University of New Jersey), Kevin Alexis Quiusky(University of Massachusetts Chan Medical School), Toshio Asakura(Children's Hospital of Philadelphia), Kathryn L. Hassell(University of Colorado Denver), John Muthu(Kings County Hospital Center), Iuliana Shapira(SUNY Downstate Health Sciences University)
Cited by 21
Related Papers
Management of Sickle Cell Disease
|JAMA|2014|1.6k
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
Management of Sickle Cell Disease Summary of the 2014 Evidence-Based Report by Expert Panel Members
|Survey of Anesthesiology|2015|270
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244